- Short report
- Open Access
Successful management of dexmedetomidine for postoperative intensive care sedation in a patient with anti-NMDA receptor encephalitis: a case report and animal experiment
© The Author(s) 2016
Received: 24 January 2016
Accepted: 15 August 2016
Published: 22 August 2016
Anti-N-methyl-d-aspartate receptor (NMDA-R) encephalitis is a recently identified but increasingly recognized autoimmune paraneoplastic disease. Because these patients present complex neuropsychiatric symptoms due to NMDA-R dysfunction, the optimal methods of sedation/anesthesia remain controversial. Here, we present animal experiment data, along with a related case report, implying the safe and effective use of dexmedetomidine in patients with anti-NMDA-R encephalitis.
(1) Animal experiment: in order to investigate whether dexmedetomidine may interfere with NMDA-R activity, an NMDA antagonist (MK-801) model in rats was used to simulate anti-NMDA-R encephalitis. Administration of MK-801 produced well-characterized schizophrenia-like behaviors, i.e. hyperlocomotion and stereotyped sniffing. Ketamine, an NMDA receptor-dependent anesthetic, exaggerated both behaviors, even at sub-anesthetic doses. On the other hand, dexmedetomidine did not show any exacerbation, suggesting that dexmedetomidine has no clinically relevant interaction with the NMDA-R in vivo. (2) Case report: our patient, a 27-year-old female, was diagnosed with anti-NMDA-R encephalitis secondary to ovarian teratoma. She underwent laparoscopic ovariectomy under general anesthesia using thiopental, sevoflurane, and remifentanil, which were well tolerated. After transfer to the intensive care unit, she became increasingly agitated despite repeated boluses of intravenous fentanyl. Infusion of dexmedetomidine (0.5–1.0 μg/kg/h) was started, and an adequate level of sedation was achieved uneventfully. After discontinuation of dexmedetomidine, recovery from sedation was smooth and quick without any deterioration of neurological or psychological symptoms.
Our experimental findings and the presented case suggest that dexmedetomidine may be safely used in patients with anti-NMDA-R encephalitis. Further clinical evaluation is warranted to validate this finding.
Anti-N-methyl-d-aspartate receptor (NMDA-R) encephalitis is an autoimmune disease first described in 2007 (Dalmau et al. 2011; Peery et al. 2012; Titulaer et al. 2013). It has since been increasingly recognized as one of the more common identifiable causes of encephalitis. These patients typically present with neuropsychiatric syndromes, including cognitive impairment, seizures, loss of consciousness, central hypoventilation, and autonomic nerve dysfunction. Its development is driven by an autoimmune reaction primarily against the NMDA-R. Anti-NMDA-R encephalitis is frequently a paraneoplastic syndrome; a recent multi-institutional observational study has shown that 38 % of patients have presence of a tumor, of which 94 % were ovarian teratomas (Dalmau et al. 2011). Initial therapy includes high-dose steroids, immunoglobulin, and plasma exchange, as well as removal of any causative neoplasm if present. Therefore, during the acute phase, most patients may undergo a surgical procedure and intensive care support, thus requiring general anesthesia and sedation. However, the optimal anesthetics/sedation methods for patients with anti-NMDA-R encephalitis remain to be established (Pryzbylkowski et al. 2011; Kawano et al. 2011; Lapébie et al. 2014; Broderick et al. 2014; Simon 2014).
The NMDA-Rs play a crucial role in controlling synaptic plasticity and memory function (Paoletti et al. 2013). The functional NMDA-R is composed of both the NR1 and NR2 subunits. The development of anti-NMDA-R encephalitis is associated with antibodies against NR1/NR2 heteromers, which reduce NMDA-R density by an increase in receptor movement into the plasma membrane, i.e., internalization (Hughes et al. 2010; van Coevorden-Hameete et al. 2014). The NMDA-Rs are also considered to be an important target of the most frequently used inhaled and non-inhaled anesthetics that inhibit its functions (Franks 2008). Therefore, sedative/anesthetic agents that act via antagonism of the NMDA-R may potentially aggravate the disease symptoms (Pryzbylkowski et al. 2011; Simon 2014).
Dexmedetomidine is now widely used to provide sedation, analgesia, and anti-sympathetic effects without respiratory depression during the perioperative period (Carollo et al. 2008). Additionally, recent studies suggest that dexmedetomidine exerts neuroprotective effects against brain injury in the central nervous system (Ma et al. 2004; Degos et al. 2013). The major sedative and antinociceptive effects of dexmedetomidine are due to its stimulation of α2-adrenoceptors located in the locus coeruleus (Hunter et al. 1997). Therefore, dexmedetomidine may be suitable for postoperative sedation of patients with anti-NMDA-R encephalitis. However, the interaction between dexmedetomidine and NMDA-R activity remains under investigation, and there have been no reports on the clinical use of dexmedetomidine in the patients with anti-NMDA-R encephalitis.
In this report, we present experimental data regarding the use of dexmedetomidine under simulated NMDA-R hypo-functions in rats and a clinical case of anti-NMDA-R encephalitis successfully sedated with dexmedetomidine postoperatively.
It is well reported that antagonists of the NMDA-R, such as phencyclidine, produce symptoms similar to those observed in patients with anti-NMDA-R encephalitis (Dalmau et al. 2011). Furthermore, an NMDA-R antagonist, MK-801, induces schizophrenia-like symptoms and is widely used as a rodent model of schizophrenia (Andiné et al. 1999). Using this animal model, we investigated whether dexmedetomidine can be safely used under NMDA-R-deficient conditions, a mimic of anti-NMDA-R encephalitis.
All procedures were approved by the Kochi University Animal Experiment Committee. For the rat model of psychosis, male Sprague–Dawley rats (6 weeks old, body weight: 145–180 g) were intraperitoneally (i.p.) injected with MK-801 (Sigma-Aldrich, St. Louis, MO). Injections of 0.01, 0.02, or 0.05 mg/kg dexmedetomidine (n = 8 for each dose) were tested in this study. The NMDA-R antagonist anesthetic, ketamine, was used as a positive control at doses of 10, 50, and 100 mg/kg (n = 2–8, as indicated in Results).
On the day of surgery, the patient underwent general anesthesia with endotracheal intubation, consisting of induction with thiopental, fentanyl, and rocuronium, followed by maintenance with sevoflurane (1.5–2.0 %) and remifentanil infusion. Surgery was uneventful and completed in 84 min, and the pathology confirmed mature teratoma. Consistent with a previous case report in Japan (Kawano et al. 2011), our case demonstrated that sevoflurane could maintain anesthesia without complication. Seven minutes after discontinuation of sevoflurane at the end of surgery, responses to verbal commands and spontaneous respiration via the tracheostomy cannula were observed, and she was transferred to the intensive care unit (ICU). However, the patient condition worsened with agitated, oral-lingual-facial dyskinesia, limb dystonia, as well as developed tachycardia and hypertension. Analgesia was attempted with repeated boluses of 50 µg fentanyl (total of 4 times), but failed to improve her symptoms. Dexmedetomidine was then infused at 1.0 μg/kg/h for the first hour, followed by maintenance infusion of 0.5 μg/kg/h. In this case, we chose to avoid the loading dose of dexmedetomidine to prevent any potential side-effects such as hypertension. An adequate level of sedation (Ramsay sedation score ≥3) was achieved without supplemental sedatives or analgesics. Upon sedation, hemodynamics and arterial blood gasses were stabilized. The day after surgery, the patient was responsive to verbal stimuli 15 min after discontinuation of dexmedetomidine infusion. The following postoperative course was uncomplicated, and she was discharged from the ICU on postoperative day 3. The patient showed steady clinical improvement, and was discharged from the hospital on postoperative day 51, with near complete recovery to her premorbid state.
Anti-NMDA receptor encephalitis is now thought to be caused by the disruption of NMDA function by anti-NMDA autoantibodies (Dalmau et al. 2011; Peery et al. 2012; Titulaer et al. 2013). It is frequently a paraneoplastic syndrome and surgical removal of tumor is associated with better outcomes. Since the most common used anesthetics/sedatives interact with NMDA receptor, it’s suspected that these anesthetics/sedatives leads to worsen the disease symptoms. More recent case reports indicated that general anesthesia with propofol or sevoflurane may be well tolerated (Pryzbylkowski et al. 2011; Kawano et al. 2011; Lapébie et al. 2014; Broderick et al. 2014; Simon 2014). On the other hand, there have been no reports concerning postoperative intensive care sedation of patients with anti-NMDA-R encephalitis. In this report, we first described a single case showing that dexmedetomidine may contribute to improve the symptoms of anti-NMDA-R encephalitis exaggerated after surgery while we cannot rule out the possibility that this symptoms were also associated with postoperative delirium. Nevertheless, our findings imply that dexmedetomidine is safe and suitable for postoperative sedation, and allows stable hemodynamic responses in patients with anti-NMDA-R encephalitis.
The data of animal experiment suggest that dexmedetomidine has no clinically relevant interaction with the NMDA-R in vivo. These results may provide mechanistic support for the present case, i.e., a sedative dose of dexmedetomidine may be safely used in patients with anti-NMDA-R encephalitis. In addition, the sedative dose of dexmedetomidine could attenuated MK-801-induced psychotic behavior (Fig. 4a, b). Consistent with our observations, it has been reported that clonidine, another clinically available α2 adrenergic agonist, could protect against MK-801-induced neurotoxicity (vacuole reaction) in rat retrosplenial cortex (Farber et al. 2002). Furthermore, the most significant side-effects of dexmedetomidine are hypotension and bradycardia (Carollo et al. 2008). However, these were not observed in the present case, and postoperative autonomic hyperactivity as well as confusion could be controlled. Taking all together, our findings suggest dexmedetomidine may be a better choice for patients with anti-NMDA-R encephalitis. Nevertheless, it is difficult to determine whether these effects were a direct pharmacological interaction of the dexmedetomidine or a secondary result of sedation. Therefore, further clinical studies including case studies and treatment experience are necessary to confirm this point of view.
In addition to dexmedetomidine, sedatives commonly used in the ICU include propofol and benzodiazepines. Propofol predominantly acts via direct activation of γ-aminobutyric acid (GABA) receptors, but also weakly inhibits NMDA-R (Lapébie et al. 2014; Simon 2014). There has been one case report of a worsening of neuropsychiatric symptoms including dyskinesias and tonic–clonic generalized seizure, while no adverse consequences occurred during its intra-operative use (Lapébie et al. 2014). Further research is needed to determine what effects, if any, propofol administration may have on the symptoms of anti-NMDA-R encephalitis. Benzodiazepines bind to specific sites on postsynaptic GABA receptors, and can help manage agitation and insomnia associated with anti-NMDA-R encephalitis (Kruse et al. 2014). However, although it is unknown whether benzodiazepines were responsible for this unexpected serious coma in the present case, sustained consciousness disturbance was observed after a one single sedative dose of i.v. midazolam, a short-acting benzodiazepine. Benzodiazepines are metabolized by hepatic microsomal cytochrome P450 (CYP) enzymes, specifically CYP3A4 (Olkkola and Ahonen 2008). Therefore, we cannot rule out the possibility that our patient was a CYP3A4 poor metabolizer, resulting in increased plasma concentrations of midazolam.
In conclusion, we report for the first time successful management of a case of anti-NMDA-R encephalitis with intravenous dexmedetomidine infusion for postoperative intensive care sedation. Preclinical data using a rat model also suggested that clinically relevant doses of dexmedetomidine had no noticeable effects on neurological or psychiatric symptoms associated with NMDA-R dysfunction. Our findings imply that dexmedetomidine can be safely used as a sedative agent for patients with anti-NMDA-R encephalitis.
DY provided the case and performed clinical assessment of the patient. All authors were responsible for conception and design of the experiments. All authors were responsible for collection, analysis and interpretation of data. TK drafted the manuscript and all authors were involved in revising the manuscript. All authors read and approved the final manuscript.
The authors declare that they have no competing interests.
The patient and her mother have consented to the submission of the case report for submission to the journal.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
- Andiné P, Widermark N, Axelsson R, Nyberg G, Olofsson U, Martensson E, Sandberg M (1999) Characterization of MK-801-induced behavior as a putative rat model of psychosis. J Pharmacol Exp Ther 290:1393–1408Google Scholar
- Broderick DK, Raines DE, Nanji KC (2014) Total intravenous anesthesia using N-methyl-d-aspartate (NMDA) receptor-sparing drugs in a patient with anti-NMDA receptor encephalitis. A&A Case Rep 2:83–85View ArticleGoogle Scholar
- Carollo DS, Nossaman BD, Ramadhyani U (2008) Dexmedetomidine: a review of clinical applications. Curr Opin Anaesthesiol 21:457–461View ArticleGoogle Scholar
- Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R (2011) Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol 10:63–74View ArticleGoogle Scholar
- Degos V, Charpentier TL, Chhor V, Brissaud O, Lebon S, Schwendimann L, Bednareck N, Passemard S, Mantz J, Gressens P (2013) Neuroprotective effects of dexmedetomidine against glutamate agonist-induced neuronal cell death are related to increased astrocyte brain-derived neurotrophic factor expression. Anesthesiology 118:1123–1132View ArticleGoogle Scholar
- Farber NB, Kim SH, Dikranian K, Jiang XP, Heinkel C (2002) Receptor mechanisms and circuitry underlying NMDA antagonist neurotoxicity. Mol Psychiatry 7:32–43View ArticleGoogle Scholar
- Franks NP (2008) General anaesthesia: from molecular targets to neuronal pathways of sleep and arousal. Nat Rev Neurosci 9:370–386View ArticleGoogle Scholar
- Hughes EG, Peng X, Gleichman AJ, Lai M, Zhou L, Tsou R, Parsons TD, Lynch DR, Dalmau J, Balice-Gordon RJ (2010) Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis. J Neurosci 30:5866–5875View ArticleGoogle Scholar
- Hunter JC, Fontana DJ, Hedley LR, Jasper JR, Lewis R, Link RE, Secchi R, Sutton J, Eglen RM (1997) Assessment of the role of α2-adrenoceptor subtypes in the antinociceptive, sedative and hypothermic action of dexmedetomidine in transgenic mice. Br J Pharmacol 122:1339–1344View ArticleGoogle Scholar
- Kawano H, Hamaguchi E, Kawahito S, Tsutsumi YM, Tanaka K, Kitahata H, Oshita S (2011) Anaesthesia for a patient with paraneoplastic limbic encephalitis with ovarian teratoma: relationship to anti-N-methyl-d-aspartate receptor antibodies. Anaesthesia 66:515–518View ArticleGoogle Scholar
- Kruse JL, Jeffrey JK, Davis MC, Dearlove J, IsHak WW, Brooks JO III (2014) Anti-N-methyl-d-aspartate receptor encephalitis: a targeted review of clinical presentation, diagnosis, and approaches to psychopharmacologic management. Ann Clin Psychiatry 26:111–119Google Scholar
- Lapébie FX, Kennel C, Magy L, Projetti F, Honnorat J, Pichon N, Vignon P, François B (2014) Potential side effect of propofol and sevoflurane for anesthesia of anti-NMDA-R encephalitis. BMC Anesthesiol 14:5View ArticleGoogle Scholar
- Ma D, Hossain M, Rajakumaraswamy N, Arshad M, Sanders RD, Franks NP, Maze M (2004) Dexmedetomidine produces its neuroprotective effect via the alpha 2A-adrenoceptor subtype. Eur J Pharmacol 502:87–97View ArticleGoogle Scholar
- Olkkola KT, Ahonen J (2008) Midazolam and other benzodiazepines. Handb Exp Pharmacol 182:335–360View ArticleGoogle Scholar
- Paoletti P, Bellone C, Zhou Q (2013) NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease. Nat Rev Neurosci 14:383–400View ArticleGoogle Scholar
- Peery HE, Day GS, Dunn S, Fritzler MJ, Prüss H, De Souza C, Doja A, Mossman K, Resch L, Xia C, Sakic B, Belbeck L, Foster WG (2012) Anti-NMDA receptor encephalitis. The disorder, the diagnosis and the immunobiology. Autoimmun Rev 11:863–872View ArticleGoogle Scholar
- Pryzbylkowski PG, Dunkman WJ, Liu R, Chen L (2011) Case report: anti-N-methyl-d-aspartate receptor encephalitis and its anesthetic implications. Anesth Analg 113:1188–1191View ArticleGoogle Scholar
- Simon RW (2014) Anesthetic management and implications of pediatric patients with a diagnosis of anti-N-methyl-d-aspartate receptor encephalitis: two case reports. AANA J 82:431–436Google Scholar
- Sukhanov I, Espinoza S, Yakovlev DS, Hoener MC, Sotnikova TD, Gainetdinov RR (2014) TAAR1-dependent effects of apomorphine in mice. Int J Neuropsychopharmacol 17:1683–1693View ArticleGoogle Scholar
- Titulaer MJ, McCracken L, Gabilondo I, Armangué T, Glaser C, Iizuka T, Honig LS, Benseler SM, Kawachi I, Martinez-Hernandez E, Aguilar E, Gresa-Arribas N, Ryan-Florance N, Torrents A, Saiz A, Rosenfeld MR, Balice-Gordon R, Graus F, Dalmau J (2013) Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 12:157–165View ArticleGoogle Scholar
- van Coevorden-Hameete MH, de Graaff E, Titulaer MJ, Hoogenraad CC, Sillevis Smitt PA (2014) Molecular and cellular mechanisms underlying anti-neuronal antibody mediated disorders of the central nervous system. Autoimmun Rev 13:299–312View ArticleGoogle Scholar